Tat is produced very early upon infection (1–5), is released extracellularly (1, 4, 5) and accumulates in tissues (4) where it exerts effects on both the virus and the immune system (1–11), making it an optimal candidate for therapeutic immunization and combined antiretroviral therapy (cART) intensification (12–15). This evidence concerns the gene TAT and infection.